FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387357160> ?p ?o ?g. }

• W4387357160 abstract "Cancer survivors are at a higher risk of developing hearing loss (HL) due to older age, chemotherapy, and radiotherapy. However, the prevalence of HL among US cancer survivors remains unknown. Additionally, there is a lack of uniform HL screening guidelines for this enlarging population.To estimate the prevalence of subjective HL and objective HL by audiometry test among cancer survivors and compare them with the general population as well as to assess the performance of subjective HL questions in detecting true (ie, audiometry-confirmed) HL.In a cross-sectional design, adults between ages 20 and 80 years who had audiometry testing and responded to a hearing questionnaire from the National Health and Nutrition Examination Survey (2011-2012, 2015-2016, and 2017 to March 2020 prepandemic survey cycles) were selected. Data analysis was conducted from August 13, 2022, to July 26, 2023.The weighted prevalence of subjective HL (troublesome hearing and tinnitus) and objective HL (speech-frequency HL and high-frequency HL) by audiometry were calculated. Analyses with χ2 testing and multiadjusted logistic regression models were used to compare HL between cancer survivors and the general population. To evaluate the performance of subjective HL questions as a tool to screen for objective HL by audiometry, areas under the curve were estimated using age- and gender-adjusted logistic regression.Among the total 9337 participants (weighted n = 90 098 441; 51.2% women), 10.3% were cancer survivors. Compared with the general population, cancer survivors had a higher prevalence of troublesome hearing (adjusted odds ratio [AOR], 1.43; 95% CI, 1.11-1.84), tinnitus (AOR, 1.28; 95% CI, 0.94-1.74), speech-frequency HL (AOR, 1.43; 95% CI, 1.11-1.85), and high-frequency HL (AOR, 1.74; 95% CI, 1.29-2.34). When using the subjective HL tool and questioning regarding whether the participants were having troublesome hearing and/or tinnitus in screening for HL, the age- and gender-adjusted area under the curve was 0.88 in detecting speech-frequency HL and 0.90 in detecting high-frequency HL.The findings of this study suggest that cancer survivors have a significantly higher prevalence of HL than the general population. Two subjective HL questions could potentially accurately identify those who have true HL and provide a simple and efficient screening tool for health care professionals. Cancer survivors and their families should be educated and encouraged to discuss hearing concerns, and health care professionals should facilitate raising awareness and provide early screening and timely referral when HL is identified." @default.
• W4387357160 created "2023-10-06" @default.
• W4387357160 creator A5007368575 @default.
• W4387357160 creator A5036587861 @default.
• W4387357160 creator A5041643495 @default.
• W4387357160 creator A5043039489 @default.
• W4387357160 creator A5045853797 @default.
• W4387357160 creator A5055463165 @default.
• W4387357160 creator A5058894467 @default.
• W4387357160 creator A5064422444 @default.
• W4387357160 creator A5064479563 @default.
• W4387357160 creator A5064610995 @default.
• W4387357160 creator A5083822415 @default.
• W4387357160 creator A5092083737 @default.
• W4387357160 date "2023-10-05" @default.
• W4387357160 modified "2023-10-11" @default.
• W4387357160 title "Subjective and Objective Hearing Loss Among US Adult Cancer Survivors" @default.
• W4387357160 cites W1975176533 @default.
• W4387357160 cites W1980879738 @default.
• W4387357160 cites W1980991962 @default.
• W4387357160 cites W2014556601 @default.
• W4387357160 cites W2022897074 @default.
• W4387357160 cites W2101423314 @default.
• W4387357160 cites W2122522567 @default.
• W4387357160 cites W2123719421 @default.
• W4387357160 cites W2127038160 @default.
• W4387357160 cites W2168965546 @default.
• W4387357160 cites W2264971268 @default.
• W4387357160 cites W2291298306 @default.
• W4387357160 cites W2415005901 @default.
• W4387357160 cites W2466806233 @default.
• W4387357160 cites W2561119966 @default.
• W4387357160 cites W2565496688 @default.
• W4387357160 cites W2584761797 @default.
• W4387357160 cites W2772067345 @default.
• W4387357160 cites W2801302348 @default.
• W4387357160 cites W2802471242 @default.
• W4387357160 cites W2900583912 @default.
• W4387357160 cites W2949496483 @default.
• W4387357160 cites W2970380239 @default.
• W4387357160 cites W2971543624 @default.
• W4387357160 cites W2987803460 @default.
• W4387357160 cites W3025282211 @default.
• W4387357160 cites W3043752042 @default.
• W4387357160 cites W3046498608 @default.
• W4387357160 cites W3080501551 @default.
• W4387357160 cites W3093379093 @default.
• W4387357160 cites W3095212529 @default.
• W4387357160 cites W3101706093 @default.
• W4387357160 cites W3103257906 @default.
• W4387357160 cites W3137266102 @default.
• W4387357160 cites W3138936304 @default.
• W4387357160 cites W3175118018 @default.
• W4387357160 cites W3209564082 @default.
• W4387357160 cites W4206972507 @default.
• W4387357160 cites W4220713705 @default.
• W4387357160 cites W4221127100 @default.
• W4387357160 cites W4225699210 @default.
• W4387357160 cites W4242678734 @default.
• W4387357160 cites W4247508841 @default.
• W4387357160 cites W4287104495 @default.
• W4387357160 cites W4288077643 @default.
• W4387357160 cites W4304688267 @default.
• W4387357160 cites W4385621920 @default.
• W4387357160 doi "https://doi.org/10.1001/jamaoto.2023.2941" @default.
• W4387357160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37796484" @default.
• W4387357160 hasPublicationYear "2023" @default.
• W4387357160 type Work @default.
• W4387357160 citedByCount "0" @default.
• W4387357160 crossrefType "journal-article" @default.
• W4387357160 hasAuthorship W4387357160A5007368575 @default.
• W4387357160 hasAuthorship W4387357160A5036587861 @default.
• W4387357160 hasAuthorship W4387357160A5041643495 @default.
• W4387357160 hasAuthorship W4387357160A5043039489 @default.
• W4387357160 hasAuthorship W4387357160A5045853797 @default.
• W4387357160 hasAuthorship W4387357160A5055463165 @default.
• W4387357160 hasAuthorship W4387357160A5058894467 @default.
• W4387357160 hasAuthorship W4387357160A5064422444 @default.
• W4387357160 hasAuthorship W4387357160A5064479563 @default.
• W4387357160 hasAuthorship W4387357160A5064610995 @default.
• W4387357160 hasAuthorship W4387357160A5083822415 @default.
• W4387357160 hasAuthorship W4387357160A5092083737 @default.
• W4387357160 hasConcept C121608353 @default.
• W4387357160 hasConcept C126322002 @default.
• W4387357160 hasConcept C142052008 @default.
• W4387357160 hasConcept C142724271 @default.
• W4387357160 hasConcept C144024400 @default.
• W4387357160 hasConcept C149923435 @default.
• W4387357160 hasConcept C151956035 @default.
• W4387357160 hasConcept C156957248 @default.
• W4387357160 hasConcept C2776992516 @default.
• W4387357160 hasConcept C2779874844 @default.
• W4387357160 hasConcept C2780493683 @default.
• W4387357160 hasConcept C2780554537 @default.
• W4387357160 hasConcept C2908647359 @default.
• W4387357160 hasConcept C548259974 @default.
• W4387357160 hasConcept C71924100 @default.
• W4387357160 hasConcept C99454951 @default.
• W4387357160 hasConceptScore W4387357160C121608353 @default.
• W4387357160 hasConceptScore W4387357160C126322002 @default.

• next